Vertex Pharmaceuticals VRTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's EPS (diluted)?
- Vertex Pharmaceuticals (VRTX) reported EPS (diluted) of $4.02 in Q1 2026.
- How has Vertex Pharmaceuticals's EPS (diluted) changed year-over-year?
- Vertex Pharmaceuticals's EPS (diluted) increased by 61.4% year-over-year, from $2.49 to $4.02.
- What is the long-term trend for Vertex Pharmaceuticals's EPS (diluted)?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's EPS (diluted) has grown at a 19.4% compound annual growth rate (CAGR), from $9.01 to $15.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.